Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Leukemia 3Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

ibrutinib 5fludarabine 4Rituximab 4Lenalidomide 3Busulfan 3thymoglobulin 2fludarabine phosphate 2blinatumomab 2Vincristine 2Methotrexate 2Melphalan 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2tozasertib 1sargramostim 1romiplostim 1pirtobrutinib 1pegaspargase 1palbociclib 1ofatumumab 1obinutuzumab 1mocetinostat 1lirilumab 1forodesine 1fenebrutinib 1enzastaurin 1duvelisib 1Stem Cell Transplantation 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphoid × forodesine × Clear all
NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡